These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 37744474)

  • 1. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
    Zhang X; Liu S; Li Y; Wang Y; Tian M; Liu G
    PLoS One; 2016; 11(6):e0156393. PubMed ID: 27304904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
    Xie Z; Hu J; Gu H; Li M; Chen J
    Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
    Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
    Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
    Dai M; Dai S; Gu L; Xiang Z; Xu A; Lu S; Yang Y; Zhou C
    J Clin Res Pediatr Endocrinol; 2024 Sep; 16(3):323-333. PubMed ID: 38828884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.